A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2023-10-31
DOI
10.1080/14740338.2023.2274420
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma
- (2023) Hanley N. Abramson INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma
- (2023) Edward R. Scheffer Cliff et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
- (2023) Sham Mailankody et al. NATURE MEDICINE
- The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
- (2023) Mirco J. Friedrich et al. CANCER CELL
- Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
- (2023) Rafael Fonseca et al. Clinical Lymphoma Myeloma & Leukemia
- Determinants of response and resistance to T cell-engaging therapies in multiple myeloma
- (2023) Shonali Midha et al. Nature Reviews Clinical Oncology
- Long-term outcomes following CAR T cell therapy: what we know so far
- (2023) Kathryn M. Cappell et al. Nature Reviews Clinical Oncology
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
- (2023) Jesús San-Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
- (2023) Paula Rodriguez-Otero et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infectious complications of bispecific antibody therapy in patients with multiple myeloma
- (2023) Beatrice Z. Sim et al. Blood Cancer Journal
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- (2023) Farah Mazahreh et al. Blood Advances
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
- (2023) Alexander M. Lesokhin et al. NATURE MEDICINE
- Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
- (2023) Gemma Reynolds et al. Blood Advances
- Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus from International Myeloma Foundation Expert Roundtable
- (2022) AK Nooka et al. Clinical Lymphoma Myeloma & Leukemia
- Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
- (2022) Muthulekha Swamydas et al. Journal of Hematology & Oncology
- NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
- (2022) Natalie S. Callander et al. Journal of the National Comprehensive Cancer Network
- Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma
- (2022) Muhamed Baljevic et al. Journal of the National Comprehensive Cancer Network
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
- (2022) Paul G Richardson et al. LANCET ONCOLOGY
- Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
- (2022) Fredrik H Schjesvold et al. Lancet Haematology
- Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
- (2022) Meletios A. Dimopoulos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
- (2022) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
- (2022) P. Moreau et al. ANNALS OF ONCOLOGY
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
- (2022) Thierry Facon et al. HEMATOLOGICAL ONCOLOGY
- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
- (2022) Adam D. Cohen et al. Blood Cancer Journal
- Belantamab mafodotin associated corneal microcyst-like epithelial changes
- (2022) Katherine Chuang et al. American Journal of Ophthalmology Case Reports
- Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma
- (2022) Jithma P. Abeykoon et al. BRITISH JOURNAL OF HAEMATOLOGY
- FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
- (2022) Andrea C. Baines et al. CLINICAL CANCER RESEARCH
- Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis
- (2022) Ivan Spicka et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.
- (2022) Attaya Suvannasankha et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).
- (2022) Paula Rodríguez-Otero et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results.
- (2022) Hang Quach et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.
- (2022) Thomas G. Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis.
- (2022) Hang Quach et al. JOURNAL OF CLINICAL ONCOLOGY
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- (2022) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
- (2022) Shaji Kumar et al. Blood Cancer Journal
- Corneal toxicity with belantamab mafodotin: Multi‐institutional real‐life experience
- (2022) Meera Mohan et al. AMERICAN JOURNAL OF HEMATOLOGY
- Corneal Toxicity Associated With Belantamab Mafodotin Is Not Restricted to the Epithelium: Neuropathy Studied With Confocal Microscopy
- (2022) Julia Aschauer et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
- (2022) Tamir Shragai et al. BRITISH JOURNAL OF HAEMATOLOGY
- Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
- (2022) Shlomit Kfir-Erenfeld et al. CLINICAL CANCER RESEARCH
- NK cell therapy in relapsed refractory multiple myeloma
- (2022) Elham Roshandel et al. CLINICAL IMMUNOLOGY
- A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
- (2022) Anita D'Souza et al. JOURNAL OF CLINICAL ONCOLOGY
- GPRC5D-Targeted CAR T Cells for Myeloma
- (2022) Sham Mailankody et al. NEW ENGLAND JOURNAL OF MEDICINE
- High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
- (2022) Jahanzaib Khwaja et al. Blood Cancer Journal
- Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
- (2022) Kevin Charles Miller et al. Blood Cancer Journal
- Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
- (2022) Sagar Lonial et al. Lancet Haematology
- Bispecific antibodies in multiple myeloma treatment: A journey in progress
- (2022) Shih-Feng Cho et al. Frontiers in Oncology
- Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance
- (2022) Mateo Mejia Saldarriaga et al. Frontiers in Oncology
- Cumulative Incidence and Relative Risk of Infection in Multiple Myeloma Patients Treated with anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-Analysis
- (2022) Stephanos Vassilopoulos et al. Open Forum Infectious Diseases
- Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review
- (2022) Matthew Lyall et al. JMIR Cancer
- Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
- (2022) Guido Lancman et al. BLOOD
- A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
- (2022) Peter M. Voorhees et al. BLOOD
- Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
- (2022) Suzanne Trudel et al. BLOOD
- RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
- (2022) Carmelo Carlo-Stella et al. BLOOD
- Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
- (2022) Noopur Raje et al. BLOOD
- Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
- (2022) Niels WCJ Van De Donk et al. BLOOD
- Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- (2022) Ajai Chari et al. BLOOD
- Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
- (2022) Ajay K. Nooka et al. BLOOD
- Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
- (2022) Suzanne Trudel et al. BLOOD
- Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
- (2022) Sagar Lonial et al. BLOOD
- Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2022) Isaac W. Boss et al. BLOOD
- Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
- (2022) Sandy W. Wong et al. BLOOD
- Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
- (2022) Cyrille Touzeau et al. BLOOD
- Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma
- (2022) Mohamed Elmeliegy et al. BLOOD
- Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
- (2022) Paul G. Richardson et al. BLOOD
- KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
- (2022) Saad Usmani et al. BLOOD
- Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
- (2022) Naresh Bumma et al. BLOOD
- Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
- (2022) Emma Searle et al. BLOOD
- French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
- (2022) Benoit Ferment et al. BLOOD
- Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
- (2022) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
- (2022) Rossella Iula et al. Frontiers in Oncology
- Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
- (2022) Adrián Alegre et al. Oncology and Therapy
- Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma
- (2022) Neha Narayan et al. JAAD Case Reports
- Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
- (2021) Leona Yamamoto et al. Frontiers in Oncology
- Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2021) M.A. Dimopoulos et al. ANNALS OF ONCOLOGY
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
- (2021) Holger W. Auner et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
- (2021) Thomas G. Martin et al. CANCER
- Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
- (2021) Sara Bringhen et al. LEUKEMIA RESEARCH
- A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
- (2021) Joseph Mikhael et al. Blood Cancer Journal
- Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
- (2021) Fatih M. Uckun Cancers
- Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
- (2021) Ahsan Wahab et al. Frontiers in Oncology
- Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA‐MM subgroup analysis
- (2021) Fredrik Schjesvold et al. AMERICAN JOURNAL OF HEMATOLOGY
- Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
- (2021) Simon J. Harrison et al. BRITISH JOURNAL OF HAEMATOLOGY
- Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
- (2021) Sagar Lonial et al. CANCER
- Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
- (2021) Ajai Chari et al. Clinical Lymphoma Myeloma & Leukemia
- Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma
- (2021) Geraldine Ferron‐Brady et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study
- (2021) Paul G Richardson et al. Future Oncology
- Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
- (2021) Saad Z Usmani et al. LANCET
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
- (2021) Philippe Moreau et al. LANCET
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
- (2021) Saad Z. Usmani et al. LEUKEMIA
- Advances in viral oncolytics for treatment of multiple myeloma – a focused review
- (2021) Ayesha Sarwar et al. Expert Review of Hematology
- Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
- (2021) Luciano J Costa et al. Blood Advances
- Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography
- (2021) Wataru Matsumiya et al. American Journal of Ophthalmology Case Reports
- DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
- (2021) Thibaud Prawitz et al. ADVANCES IN THERAPY
- Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
- (2021) Sosana Delimpasi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
- (2021) Suzanne Trudel et al. BLOOD
- Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2
- (2021) Yael C. Cohen et al. BLOOD
- Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
- (2021) Thomas Martin et al. BLOOD
- The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers
- (2021) Tadeusz Dyba et al. EUROPEAN JOURNAL OF CANCER
- Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
- (2021) Larry D Anderson Jr Future Oncology
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
- (2021) Marcelo Capra et al. HAEMATOLOGICA
- Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
- (2021) Oliver Van Oekelen et al. NATURE MEDICINE
- “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
- (2021) I. Vaxman et al. Blood Cancer Journal
- Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
- (2021) Arthur Bobin et al. Cancers
- Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
- (2021) Nicola Sgherza et al. Frontiers in Oncology
- Risk of infections with B cell maturation antigen (BCMA) directed Immunotherapy in Multiple Myeloma
- (2021) Meera Mohan et al. Blood Advances
- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- Characterisation of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial
- (2020) Rakesh Popat et al. HAEMATOLOGICA
- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
- (2020) Maria Gavriatopoulou et al. LEUKEMIA
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
- (2020) Nina Shah et al. LEUKEMIA
- Immunotherapy of multiple myeloma
- (2020) Simone A. Minnie et al. JOURNAL OF CLINICAL INVESTIGATION
- A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
- (2020) Joseph Mikhael et al. LEUKEMIA
- Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
- (2020) Meletios A. Dimopoulos et al. LEUKEMIA
- Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study
- (2020) Paul G Richardson et al. Lancet Haematology
- Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations
- (2020) Selina J. Chavda et al. BRITISH JOURNAL OF HAEMATOLOGY
- Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor
- (2020) Joseph Mikhael et al. Clinical Lymphoma Myeloma & Leukemia
- Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
- (2020) Fredrik H. Schjesvold et al. HAEMATOLOGICA
- Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
- (2020) Meletios A Dimopoulos et al. BLOOD
- Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
- (2020) Kazutaka Sunami et al. CANCER SCIENCE
- Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
- (2020) Paul G. Richardson et al. Blood Cancer Journal
- Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients
- (2020) Rebecca B. Bausell et al. Eye & Contact Lens-Science and Clinical Practice
- Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
- (2020) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery
- (2020) Antoine Rousseau et al. OPHTHALMOLOGY
- Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
- (2019) Thomas Martin et al. Blood Cancer Journal
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
- (2019) Joseph Mikhael et al. BLOOD
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)
- (2019) George R. Nahas et al. LEUKEMIA & LYMPHOMA
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- (2018) Dan T. Vogl et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
- (2018) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab
- (2018) Ajay K. Nooka et al. Journal of Oncology Practice
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- (2018) Nizar J. Bahlis et al. BLOOD
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
- (2018) Paul G. Richardson et al. Blood Cancer Journal
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
- (2016) Rizwan Romee et al. Science Translational Medicine
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Management of treatment-emergent peripheral neuropathy in multiple myeloma
- (2011) P G Richardson et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search